Nuvation Bio Inc. (NUVB) Stock Price & Analysis
Nuvation Bio Inc. (NUVB) closed at USD 4.75 on Thursday, October 15, 2026, up 1.50% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.68; the Oct 15, 2026 session ranged USD 4.67–4.86 on volume of 4,822,647 shares. Market capitalization is $1.67B, with a 52-week range of USD 3.36–9.75 (NYQ). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NUVB.md
Key facts (NUVB)
- Last four reported quarters (through Jun 30, 2026): revenue $170M, net income -$150M (-88.2% margin) (SEC filings).
- 2 of 80 tracked superinvestors hold NUVB (13F, Q2 2026): 0 new, 0 added, 0 reduced, 2 unchanged.
- Analysts: Buy (mean 1.85 on a 1–5 scale) (13 analysts), mean target USD 13 (range 7–21).
- Total return with dividends: 1Y +30.9% vs S&P 500 +18.1%; 5Y -50.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-02, EPS estimate USD -0.09, revenue estimate $34.8M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NUVB)
| USD | FY2021 | FY2022 | FY2024 | FY2025 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0K | $7.9M | $62.9M | $170M |
| Gross profit | — | — | $0K | $795K | — | — |
| Operating income | -$93.3M | -$120M | -$99.8M | -$593M | -$213M | -$138M |
| Net income | -$86.8M | -$104M | -$75.8M | -$568M | -$205M | -$150M |
| EPS (diluted) | -$0.44 | -$0.48 | -$0.35 | -$2.11 | -$0.60 | — |
| Free cash flow | — | — | — | -$130M | -$181M | — |
| Gross margin | — | — | — | 10.1% | — | — |
| Operating margin | — | — | — | -7527.3% | -338.7% | -81.0% |
| Net margin | — | — | — | -7213.8% | -325.3% | -88.2% |
| Revenue growth | — | — | — | — | +699.0% | — |
| Cash + short-term investments | $765M | $661M | $611M | $503M | $529M | — |
| Total debt | — | — | — | — | $52.9M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NUVB)
P/S 9.8x · EV/Sales 7.4x · P/B 6.6x · Earnings yield -8.98% · Net cash $412M · EV $1.26B
Superinvestors (SEC 13F-HR, Q2 2026) (NUVB)
2 of 80 tracked investors hold NUVB. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| David Abrams | Abrams Capital Management | 0.13% | $7.2M | Unchanged |
| David Einhorn | Greenlight Capital | 0.01% | $199K | Unchanged |
Analysts (NUVB)
Consensus Buy (mean 1.85 on a 1–5 scale), 13 analysts; mean target USD 13 (low 7, high 21).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | Citigroup | Initiated | Buy | $12 |
| 2026-09-16 | Citizens | Reiterated | Market Outperform | $10 |
| 2026-09-16 | Wedbush | Reiterated | Outperform | $11 |
| 2026-08-21 | Cantor Fitzgerald | Initiated | Overweight | |
| 2026-08-18 | JP Morgan | Initiated | Overweight | $13 |
| 2026-08-07 | RBC Capital | Target raised | Outperform | $19 → $20 |
| 2026-07-27 | HC Wainwright & Co. | Target raised | Buy | $17 → $21 |
| 2026-07-23 | Wedbush | Reiterated | Outperform | $11 |
| 2026-07-07 | RBC Capital | Target lowered | Outperform | $20 → $19 |
| 2026-07-07 | Truist Securities | Target raised | Buy | $12 → $13 |
Total return (dividends reinvested) (NUVB)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +30.9% | -50.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +31.0% | -13.0% |
| Volatility (annualized) | 81.0% | 74.5% |
| Max drawdown | -57.5% (Dec 2025→Mar 2026) | -89.3% (Oct 2021→Oct 2023) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 4.75 |
|---|---|
| Change | ▲ 1.50% (up) |
| Previous Close | USD 4.68 |
| Open | USD 4.74 |
| Day Range | USD 4.67 – 4.86 |
| 52-Week Range | USD 3.36 – 9.75 |
| Volume | 4,822,647 shares |
| Market Cap | $1.67B |
| Exchange | NYQ |
Technical Analysis (NUVB)
Nexqual's technical model rates NUVB "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.3 (oversold) |
| vs SMA50 | Below (USD 6.05) |
| MACD | -0.39 (negative) |
Analyst Ratings (NUVB)
Wall Street analysts rate NUVB "Buy" based on 13 analysts, with a mean price target of USD 13 (range USD 7–21), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 13 |
| High Target | USD 21 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 12 / 1 / 0 |
Earnings (NUVB)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD -0.09 |
| Revenue Estimate | $34.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.15 vs est -0.12 ▼ miss |
| 2026-03-31 | USD 0.04 vs est 0.05 ▼ miss |
| 2025-12-31 | USD -0.09 vs est -0.05 ▼ miss |
| 2025-09-30 | USD -0.14 vs est -0.15 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (NUVB)
| Total Revenue | $169.90M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +555.60% |
| Gross Margin | +88.18% |
| Operating Margin | -161.06% |
| Profit Margin | -88.19% |
| ROE | -47.81% |
| Debt / Equity | 1.64 |
| Current Ratio | 8.37 |
| Total Cash | $660.96M |
| Total Debt | $416.26M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$181.43M (-288.4% of revenue) |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (NUVB)
Nexqual rates Nuvation Bio Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Strong — Revenue +699% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $661M cash vs $416M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$181M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -48%, ROA -12.4% |
Ownership (NUVB)
| Insider Ownership | +17.19% |
|---|---|
| Institutional Ownership | +67.63% |
| Shares Outstanding | 350.12M |
| Float | 263.65M |
| Short % of Float | +27.61% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (NUVB)
Nuvation Bio Inc. is led by David T. Hung (age 67), Founder, President, CEO & Chairman, per Nexqual as of October 16, 2026 at 05:19 UTC.
| Founder, President, CEO & Chairman | David T. Hung (age 67) |
|---|---|
| CFO & Principal Financial Officer | Philippe Pierre Sauvage (age 47) |
| Chief Scientific Officer | Gary Hattersley (age 58) |
| Vice President of Corporate Development & Investor Relations | Robert DeVita |
Major Backers & Investors (NUVB)
Notable institutional backers of Nuvation Bio Inc. include FMR, LLC, Fidelity, Decheng Capital LLC, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.88% |
| Fidelity | 8.54% |
| Decheng Capital LLC | 7.39% |
| Omega Fund Management, Llc | 2.3% |
| American Century Companies Inc | 2.26% |
| Laurion Capital Management, LP | 2.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.91% |
| Vanguard Group | 6.7% |
| State Street | 2.1% |
| Geode Capital | 1.78% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt